Anti-cancer Effects of a Novel Curcumin Derivative, 4,4-Diallyl Curcumin Bis(2,2-Hydroxymethyl)Propanoate (35e), on Radio-resistant Colorectal Cancer Cells
Failure of radiotherapy is a major factor leading to poor prognosis in colorectal cancer. This study investigated the anticancer effects of a novel curcumin derivative, 4,4-diallyl curcumin bis(2,2-hydroxymethyl)propanoate (35e), on radio-resistant colorectal cancer cells (HT29/RR). HT29/RR cells we...
Saved in:
Published in | Anticancer research Vol. 45; no. 7; pp. 2891 - 2904 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Greece
01.07.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Failure of radiotherapy is a major factor leading to poor prognosis in colorectal cancer. This study investigated the anticancer effects of a novel curcumin derivative, 4,4-diallyl curcumin bis(2,2-hydroxymethyl)propanoate (35e), on radio-resistant colorectal cancer cells (HT29/RR).
HT29/RR cells were established by exposing parental HT29 cells to repeated irradiation cycles. The cytotoxic effects of 35e were evaluated using MTT assays, DAPI and TUNEL staining, caspase-3 and caspase-9 activities assays, and RNA sequencing analysis.
Treatment with 35e significantly reduced cell viability in a dose-dependent manner. Apoptosis induction was confirmed by chromatin condensation and DNA fragmentation (DAPI/TUNEL staining), alongside elevated caspase-3 and caspase-9 activities. RNA sequencing analysis revealed that 35e treatment altered gene expression, down-regulating pro-survival genes and up-regulating pro-apoptotic genes. Pathway analysis indicated that 35e regulated the EGFR/PI3K/AKT and NF-κB pathways, contributing to suppressed proliferation and enhanced apoptosis.
35e effectively inhibits growth and induces apoptosis in radio-resistant colorectal cancer cells by targeting multiple signaling pathways. These findings suggest that 35e is a promising therapeutic candidate for overcoming radio-resistance in colorectal cancer. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0250-7005 1791-7530 1791-7530 |
DOI: | 10.21873/anticanres.17657 |